{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:21:30Z","timestamp":1792581690786,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","funder":[{"DOI":"10.13039\/100018090","name":"Bayer Korea","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018090","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the clinical outcomes of a treat-and-extend regimen using aflibercept for Type 3 macular neovascularization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this prospective phase four clinical trial, 25 patients with Type 3 macular neovascularization underwent treat-and-extend with aflibercept for over 76 weeks. After an initial 3 loading injections, the interval between injections was extended by 2 weeks, up to a maximum of 16 weeks, provided there was no recurrence. If recurrence occurred, the interval was reduced to 8 weeks, regardless of the previous interval. The primary outcome measure was the change in best-corrected visual acuity from diagnosis to 76 weeks. Secondary outcomes included the number of injections, changes in central retinal thickness over 76 weeks, and changes in the incidence of subretinal fluid, intraretinal fluid, subretinal hyperreflective material, and serous pigment epithelial detachment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean number of injections over 76 weeks was 8.5 \u00b1 0.8. Baseline best-corrected visual acuity was 53.6 \u00b1 13.0 letters, which improved by 4.6 letters to 58.2 \u00b1 15.6 letters at 76 weeks (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.044). Central retinal thickness significantly decreased from 488.1 \u00b1 204.2\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m at diagnosis to 247.8 \u00b1 57.0\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m at 76 weeks (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The incidences of subretinal fluid, intraretinal fluid, subretinal hyperreflective material, and serous pigment epithelial detachment decreased markedly from 56%, 100%, 52%, and 84% at baseline to 8%, 4%, 4%, and 8%, respectively, at 76 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Treat-and-extend with aflibercept for &gt;76 weeks improved best-corrected visual acuity and significantly reduced central retinal thickness in those with Type 3 macular neovascularization. At 76 weeks, most patients maintained a dry macula, indicating that this approach is an effective and efficient treatment strategy for Type 3 macular neovascularization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004571","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T16:00:17Z","timestamp":1751040017000},"page":"2018-2026","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["OUTCOMES OF TREAT-AND-EXTEND USING AFLIBERCEPT IN TYPE 3 MACULAR NEOVASCULARIZATION"],"prefix":"10.1097","volume":"45","author":[{"given":"Jae Hui","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Joo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251021","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","article-title":"Retinal angiomatous proliferation in age-related macular degeneration","volume":"21","author":"Yannuzzi","year":"2001","journal-title":"Retina"},{"key":"R2-20251021","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/IAE.0b013e3181669504","article-title":"Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation","volume":"28","author":"Freund","year":"2008","journal-title":"Retina"},{"key":"R3-20251021","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1097\/IAE.0000000000002239","article-title":"Long-term visual changes in initially stronger fellow eyes in patients with unilateral type 3 neovascularization","volume":"39","author":"Kim","year":"2019","journal-title":"Retina"},{"key":"R4-20251021","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s00417-020-05028-5","article-title":"Difference in treatment burden of neovascular age-related macular degeneration among different types of neovascularization","volume":"259","author":"Lee","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R5-20251021","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/IAE.0b013e3181bfbd46","article-title":"\u201cTreat and extend\u201d dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation","volume":"29","author":"Engelbert","year":"2009","journal-title":"Retina"},{"key":"R6-20251021","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","article-title":"Treat-and-extend regimens with anti-vegf agents in retinal diseases: a literature Review and consensus recommendations","volume":"35","author":"Freund","year":"2015","journal-title":"Retina"},{"key":"R7-20251021","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000453281","article-title":"One-year outcomes of the treat-and-extend approach with aflibercept in age-related macular degeneration: effects on typical choroidal neovascularization and retinal angiomatous proliferation","volume":"236","author":"Castro-Navarro","year":"2016","journal-title":"Ophthalmologica"},{"key":"R8-20251021","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.oret.2017.09.002","article-title":"Treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration: efficacy and macular atrophy development","volume":"2","author":"Matsumoto","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R9-20251021","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1097\/IAE.0000000000001104","article-title":"Treat-and-extend regimen with aflibercept for retinal angiomatous proliferation","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Retina"},{"key":"R10-20251021","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/IAE.0000000000002582","article-title":"Efficacy and safety of a treat-and-extend regimen with aflibercept in treatment-naive patients with type 3 neovascularization: a 52-week, single-arm, multicenter trial","volume":"40","author":"Arias","year":"2020","journal-title":"Retina"},{"key":"R11-20251021","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00417-019-04306-1","article-title":"Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment","volume":"257","author":"Kim","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R12-20251021","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1167\/iovs.15-18837","article-title":"Geographic atrophy and activity of neovascularization in retinal angiomatous proliferation","volume":"57","author":"Baek","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-20251021","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00417-019-04373-4","article-title":"Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis","volume":"257","author":"Kim","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R14-20251021","first-page":"480","article-title":"Abrupt visual loss during anti-vascular endothelial growth factor treatment for type 3 neovascularization","volume":"12","author":"Kim","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"R15-20251021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1080\/08820538.2018.1511814","article-title":"Early recurrent hemorrhage in submacular hemorrhage secondary to type 3 neovascularization or retinal angiomatous proliferation: incidence and influence on visual prognosis","volume":"33","author":"Kim","year":"2018","journal-title":"Semin Ophthalmol"},{"key":"R16-20251021","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/IAE.0000000000001268","article-title":"An updated staging system of type 3 neovascularization using spectral domain optical coherence tomography","volume":"36","author":"Su","year":"2016","journal-title":"Retina"},{"key":"R17-20251021","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1097\/IAE.0000000000001876","article-title":"Difference in treatment outcomes according to optical coherence tomography-based stages in type 3 neovascularization (retinal angiomatous proliferation)","volume":"38","author":"Kim","year":"2018","journal-title":"Retina"},{"key":"R18-20251021","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/IAE.0000000000003797","article-title":"Incidence and timing of pigment epithelial detachment and subretinal fluid development in type 3 macular neovascularization associated with age-related macular degeneration","volume":"43","author":"Kim","year":"2023","journal-title":"Retina"},{"key":"R19-20251021","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1097\/IAE.0000000000000225","article-title":"Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients","volume":"34","author":"Shin","year":"2014","journal-title":"Retina"},{"key":"R20-20251021","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00417-022-05833-0","article-title":"Difference in characteristics and lesion reactivation between type 3 macular neovascularization with and without subretinal fluid at baseline","volume":"261","author":"Kim","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R21-20251021","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/IAE.0000000000000488","article-title":"Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography","volume":"35","author":"Nagiel","year":"2015","journal-title":"Retina"},{"key":"R22-20251021","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00417-019-04404-0","article-title":"Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study","volume":"257","author":"Augsburger","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R23-20251021","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41433-022-02264-3","article-title":"Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: updated guidance from a UK expert panel","volume":"37","author":"Bailey","year":"2023","journal-title":"Eye (Lond)"},{"key":"R24-20251021","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/bjophthalmol-2015-308074","article-title":"Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study","volume":"100","author":"Kim","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R25-20251021","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"R26-20251021","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/IAE.0000000000003010","article-title":"Long-term changes in choroidal thickness in eyes with type 3 macular neovascularization","volume":"41","author":"Kim","year":"2021","journal-title":"Retina"},{"key":"R28-20251021","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R29-20251021","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00417-018-04228-4","article-title":"Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye","volume":"257","author":"Kim","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R30-20251021","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:00:27Z","timestamp":1761073227000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004571"}},"subtitle":["A Prospective Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004571","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}